April 6, 2020
Orexo ends share buy-back program
Uppsala, Sweden – April 6, 2020. Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 s...
Read more
Read more
April 6, 2020
GenSight Biologics Provides Update on Operations in the Context of COVID-19
Paris, France, April 6, 2020, 7.30 am CET – GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, PEA-PME eligible), a biopharma company focused on discovering an...
Read more
Read more
April 3, 2020
BONESUPPORT HOLDING AB (publ) publishes 2019 Annual Report and comments on effects of COVID-19
Lund, Sweden, 15:00 CET, 3 April 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, publishes its annua...
Read more
Read more
April 2, 2020
Oncopeptides strengthens its corporate communications function by appointing Rolf Gulliksen as Global Head of Corporate Communications
STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf ...
Read more
Read more
April 1, 2020
Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021
Oslo, Norway, 1 April 2020
Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial wi...
Read more
Read more
March 31, 2020
Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
Gothenburg, March 31, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the submission of a...
Read more
Read more
March 30, 2020
Vicore submits clinical trial application for phase II trial with C21 in IPF 2020-03-30
Gothenburg, March 30, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces submission of the c...
Read more
Read more
March 27, 2020
Nordic Nanovector ASA publishes 2019 Annual Report
Oslo, Norway, 27 March 2020
On 26 March 2020, the Board of Directors of Nordic Nanovector ASA approved the company’s financial statements for 2019. The company’s 2019 Annual...
Read more
Read more
March 26, 2020
Orexo publishes the Annual Report for 2019
Uppsala, Sweden - March 26, 2020 – Orexo’s Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published. The Annual Report can be down...
Read more
Read more
March 26, 2020
Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study
STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melfluf...
Read more
Read more